Maarten IJzerman

A systematic review of methodological considerations in time to diagnosis and treatment in colorectal cancer research.

Allison Drosdowsky, Karen E Lamb, Rebecca J Bergin, Lucy Boyd, Kristi Milley, Maarten J IJzerman, Jon D Emery

Journal article  |  2023  |  Cancer Epidemiol

Research focusing on timely diagnosis and treatment of colorectal cancer is necessary to improve outcomes for people with cancer. ..

Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations.

Carina M Behr, Martijn J Oude Wolcherink, Maarten J IJzerman, Rozemarijn Vliegenthart, Hendrik Koffijberg

Journal article  |  2023  |  Pharmacoeconomics

BACKGROUND: Chest low-dose computed tomography (LDCT) is a promising technology for population-based screening because it is non-i..

Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review

Yat Hang To, Peter Gibbs, Jeanne Tie, Maarten IJzerman, Koen Degeling

Journal article  |  2023  |  COST EFFECTIVENESS AND RESOURCE ALLOCATION

OBJECTIVE: The aims of this study was to appraise the health economic evidence for adjuvant chemotherapy (AC) strategies in stage ..

Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?

Amanda Pereira-Salgado, Angelyn Anton, Fanny Franchini, Robert K Mahar, Edmond M Kwan, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun A Azad, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Christopher Steer, Stephen Brown, Peter Gibbs, Ben Tran, Maarten IJzerman

Journal article  |  2022  |  EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH

INTRODUCTION: Health economic outcomes of real-world treatment sequencing of androgen receptor-targeted agents (ARTA) and docetaxe..

The societal impact of implementing an at-home blood sampling device for chronic care patients: patient preferences and cost impact.

Deon Lingervelder, Michelle MA Kip, Eva D Wiese, Hendrik Koffijberg, Maarten J Ijzerman, Ron Kusters

Journal article  |  2022  |  BMC Health Serv Res

BACKGROUND: Diabetes mellitus, cardiovascular diseases, chronic kidney disease, and thyroid diseases are chronic diseases that req..

Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care.

Edwin Cuppen, Olivier Elemento, Richard Rosenquist, Svetlana Nikic, Maarten IJzerman, Isabelle Durand Zaleski, Geert Frederix, Lars-Åke Levin, Charles G Mullighan, Reinhard Buettner, Trevor J Pugh, Sean Grimmond, Carlos Caldas, Fabrice Andre, Ilse Custers, Elias Campo, Hans van Snellenberg, Anna Schuh, Hidewaki Nakagawa, Christof von Kalle, et al.

Journal article  |  2022  |  JCO Precis Oncol

PURPOSE: The combination of whole-genome and transcriptome sequencing (WGTS) is expected to transform diagnosis and treatment for ..

EE141 Cost-Effectiveness of TP53 and IGHV Biomarker Testing Prior to First-Line Treatment With Novel Agents for Chronic Lymphocytic Leukemia

M Vu, K Degeling, E Thompson, P Blombery, DA Westerman, M IJzerman

Journal article  |  2022  |  Value in Health

EE114 Cost-Utility Analysis of Lung Cancer Screening Combined With Cardiovascular Disease and Chronic Obstructive Pulmonary Disease Screening

C Behr, M IJzerman, MMA Kip, R Vliegenthart, H Koffijberg

Journal article  |  2022  |  Value in Health

HTA142 Potential Impact of Biomarker Guided-Decisions on Overtreatment in Immunotherapy for Non-Small Cell Lung Cancer Patients

F van Delft, H Koffijberg, M Schuurbiers, H van Rossum, M van den Heuvel, M IJzerman

Journal article  |  2022  |  Value in Health

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours

Yoon-Jung Kang, Sophie O'Haire, Fanny Franchini, Maarten IJzerman, John Zalcberg, Finlay Macrae, Karen Canfell, Julia Steinberg

Journal article  |  2022  |  SCIENTIFIC REPORTS

Immune checkpoint inhibitors have been approved in the USA for tumours exhibiting mismatch repair deficiency (dMMR), microsatellit..